Free Trial
NASDAQ:IKNA

Ikena Oncology Q2 2024 Earnings Report

Ikena Oncology logo
$1.17 -0.01 (-0.43%)
As of 02:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ikena Oncology EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Ikena Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ikena Oncology Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

Ikena Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025

Ikena Oncology Earnings Headlines

Ikena Oncology Reports Q1 Loss Amid Merger Plans
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
See More Ikena Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email.

About Ikena Oncology

Ikena Oncology (NASDAQ:IKNA) operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Ikena Oncology Profile

More Earnings Resources from MarketBeat